113 related articles for article (PubMed ID: 6804290)
21. [Effect of 2-phenoxyethanol on potency of Sabin inactivated poliomyelitis vaccine and its safety].
Bian CX; Jiang SD; Yang JY; Sun MB; Xie MX; Zhang XW; Liao GY; Li WD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):44-6. PubMed ID: 17429533
[TBL] [Abstract][Full Text] [Related]
22. Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site.
Sawyer LA; Wood D; Ferguson M; Crainic R; Beuvery EC; McInnis J; Albrecht P
Biologicals; 1997 Sep; 25(3):299-306. PubMed ID: 9324998
[TBL] [Abstract][Full Text] [Related]
23. Quantitative determination of rabies antigen by ELISA.
van der Marel P; van Wezel AL
Dev Biol Stand; 1981; 50():267-75. PubMed ID: 7341294
[TBL] [Abstract][Full Text] [Related]
24. Rat immunogenicity assay of inactivated poliovirus.
Bevilacqua JM; Young L; Chiu SW; Sparkes JD; Kreeftenberg JG
Dev Biol Stand; 1996; 86():121-7. PubMed ID: 8785941
[TBL] [Abstract][Full Text] [Related]
25. The production of inactivated poliovaccine on serially cultivated kidney cells from captive-bred monkeys.
van Wezel AL; van der Velden-de Groot CA; van Herwaarden JA
Dev Biol Stand; 1980; 46():151-8. PubMed ID: 6244995
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
[TBL] [Abstract][Full Text] [Related]
27. The concentration of poliovirus antigens for D-antigen determination.
van Ramshorst JD
Bull World Health Organ; 1967; 36(2):209-18. PubMed ID: 4965451
[TBL] [Abstract][Full Text] [Related]
28. ELISA as a possible alternative to the neutralization test for evaluating the immune response to poliovirus vaccines.
Ivanov AP; Dragunsky EM
Expert Rev Vaccines; 2005 Apr; 4(2):167-72. PubMed ID: 15889990
[TBL] [Abstract][Full Text] [Related]
29. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
[TBL] [Abstract][Full Text] [Related]
30. Proposals on the control of VERO cells used to prepare inactivated poliomyelitis vaccine.
Ménetrat JL; Chaniot S; Lefrançois S; Canale A; Chippaux A
Dev Biol Stand; 1981; 47():163-7. PubMed ID: 6785125
[TBL] [Abstract][Full Text] [Related]
31. Cultivation of second and third passage cells from Cercopithecus monkey kidneys in monolayer cultures.
Petersen I; Ladefoged P
Dev Biol Stand; 1981; 50():141-4. PubMed ID: 7341289
[TBL] [Abstract][Full Text] [Related]
32. Diffusion-in-gel enzyme-linked immunosorbent assay (DIG-ELISA). Quantification of antigen by diffusion over an antibody-coated surface.
Nygren H; Stenberg M
Scand J Clin Lab Invest; 1982 Jun; 42(4):355-9. PubMed ID: 6813949
[TBL] [Abstract][Full Text] [Related]
33. Regulation and standardization of IPV and IPV combination vaccines.
Baca-Estrada M; Griffiths E
Biologicals; 2006 Jun; 34(2):159-61. PubMed ID: 16682221
[TBL] [Abstract][Full Text] [Related]
34. Poliovirus Type 1. Preparation of a suitable antigen for gel diffusion study.
Ray S
J Indian Med Assoc; 1968 May; 50(9):403-7. PubMed ID: 4969882
[No Abstract] [Full Text] [Related]
35. Karyological characterization of WI-38 cells used in the production of vaccines.
Frieling KH; Hövel H
Dev Biol Stand; 1976 Dec 13-15; 37():181-4. PubMed ID: 1031684
[TBL] [Abstract][Full Text] [Related]
36. Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose regimen.
Salk J; Stoeckel P; van Wezel AL; Lapinleimu K; van Steenis G
Ann Clin Res; 1982 Dec; 14(5-6):204-12. PubMed ID: 7171229
[TBL] [Abstract][Full Text] [Related]
37. Potency testing of inactivated tissue culture vaccine against Japanese encephalitis using antigen capture ELISA.
Joshi AM; Walimbe AM; Banerjee K
Acta Virol; 1997 Jun; 41(3):157-9. PubMed ID: 9385404
[TBL] [Abstract][Full Text] [Related]
38. Quantitation of cell DNA in the evaluation of heteroploid cells as substrate for the preparation of killed viral vaccines.
Crainic R; Horodniceanu F; Barme M
Intervirology; 1980; 14(5-6):300-9. PubMed ID: 6265401
[TBL] [Abstract][Full Text] [Related]
39. A WHO collaborative study of immunogenicity assays of inactivated poliovirus vaccines.
Wood DJ; Heath AB
Biologicals; 1995 Dec; 23(4):301-11. PubMed ID: 8825859
[TBL] [Abstract][Full Text] [Related]
40. Detection of poliovirus, hepatitis A virus and rotavirus from sewage and water samples.
Kittigul L; Raengsakulrach B; Siritantikorn S; Kanyok R; Utrarachkij F; Diraphat P; Thirawuth V; Siripanichgon K; Pungchitton S; Chitpirom K; Chaichantanakit N; Vathanophas K
Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):41-6. PubMed ID: 11023063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
